Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?
Adaptive Biotechnologies' President and COO, Julie Rubinstein, sold 57,180 shares of company stock in April 2026, reducing her direct holdings by 12.29%. The sale was part of a series of transactions where she exercised options and immediately sold the resulting shares.
Adaptive Biotechnologies Corporation's President and COO, Julie Rubinstein, sold 57,180 shares of Common Stock between April 14 and April 16, 2026, at a weighted average price of $14.45 per share. The transaction involved exercising 44,166 options and immediately selling the resulting shares. Rubinstein's direct holdings decreased by 12.29% to 408,160 shares. This sale is part of a larger trend, as she has completed seven administrative transactions since March 2026. Adaptive Biotechnologies is a commercial-stage biotechnology company based in Seattle, focusing on immune medicine technology and diagnostics. The company's market capitalization is $2.23 billion, with revenue of $276.98 million in the last 12 months.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.